HyGro, There is nothing dubious. Everything is crystal clear. DCVAX-L works phenomenally. The real world evidence which will be presented to RA should show the efficacy of DCVax-L even much better than the p3 trial.
Ask yourself if it is coincident that the management of NVCR has been dumping their shares like crazy ever since the publication of the interim results of p3 trial in May 2018. You know why? These people are smart enough to see that their own company has a dire future ahead of them and they know the future for treating GBM will be owned by NWBO.
I would strongly recommend the counsels that are currently filing law suit against NVCR first check the personal portfolio of the c-suite. Most likely they can find NWBO.
FYI, the CEO of NVCR made over $200m by dumping his own company shares, 80% of gains happened after NWBO published the first paper on p3 trial in May 2018. No pharma experience is needed to smell something wrong here.
Market Data 
Markets 
AI
